Fig. 2From: Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLCFrequency of grade ≥ 3 AEs, including TRD (a), withdrawal toxicities (b) and overall frequency (c), according to ALK-TKIs type. TRD, treatment-related death and AEs, adverse events. Asterisks indicate statistically significant differencesBack to article page